Loading
A phase 2 trial of YL201 in prostate cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC is a phase 2 interventional study registered as NCT06241846 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2024-02-22 and due to reach its primary completion in 2027-02. Interventions recorded: YL201 for Injection. Conditions listed: Metastatic Castration-resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/